Journal: bioRxiv
Article Title: Type I interferon signaling promotes early innate control of Borrelia burgdorferi infection
doi: 10.64898/2026.02.13.705697
Figure Lengend Snippet: (A) In vitro macrophage assays. RAW 264.7 macrophages were pretreated with c-di-AMP before infection with GFP-expressing B. burgdorferi at low and high MOI. Phagocytosis was assessed by flow cytometry to determine the percentage of GFP-positive cells and GFP MFI. ( B ) Gentamicin protection assay. To assess intracellular spirochete viability, RAW 264.7 macrophages were pretreated with c-di-AMP and subsequently infected with B. burgdorferi for 2.5 hours, followed by treatment with gentamicin (200 µg/mL) to eliminate extracellular bacteria. Following washing and lysis, cell lysates were diluted in BSK-II medium and plated in 96-well plates. Intracellular bacterial viability was assessed by limiting dilution, and data are presented as percentages of B. burgdorferi- positive wells. ( C ) In vivo bacterial clearance. Mice were pretreated intradermally with c-di-AMP before infection with B. burgdorferi (1Χ10 4 spirochetes/ mouse). Spirochetal burden at the site of infection was quantified by qPCR at 5 DPI ( left ), and dissemination was assessed by the frequency of culture-positive tissues at 10 DPI ( right ). Data are presented as mean ± SD of two independent experiments (n = 3–5 mice/ group). Statistical significance was determined using a two-tailed unpaired Student’s t- test for (A) and (B) (*, P < 0.05; **, P < 0.01) and a two-tailed Fisher’s exact test for (C) (***, P < 0.001).
Article Snippet: To elucidate the effect of c-di-AMP in vivo , mice were pre-treated intradermally with c-di-AMP (50 μg/mouse; InvivoGen, tlrl-nacda) 24-hours before infection with B. burgdorferi (1 × 10 4 spirochetes/mouse).
Techniques: In Vitro, Infection, Expressing, Flow Cytometry, Bacteria, Lysis, In Vivo, Two Tailed Test
InvivoGen is a verified supplier 
InvivoGen manufactures this product 
